ASH Annual Meeting & Exposition: Lymphoma | Conference

The ZUMA-II trial suggested that patients with relapsed/refractory mantle cell lymphoma resistant to prior therapies may benefit from the autologous anti-CD19 CAR T-cell therapy.

Matthew S. Davids, MD, MMSc, discussed his phase I/II study of duvalisib combined with venetoclax for patients with relapsed/refractory CLL and SLL at the ASH Annual Meeting & Exposition.

Lisocabtagene maraleucel induced high response rates in patients with aggressive relapsed/refractory large B-cell lymphoma.